Evaluation of HIV-1 resistance to antiretroviral drugs among 150 patients after six months of therapeutic interruption

Int J STD AIDS. 2012 Feb;23(2):120-5. doi: 10.1258/ijsa.2011.011124.

Abstract

Most of the antiretroviral (ARV) studies in Brazil have been reported in treatment-experienced and naive patients rather than in the setting of treatment interruption (TI). In this study, we analysed reasons given for TI and resistance mutations occurring in 150 HIV-1-infected patients who underwent TI. Of the patients analysed, 110 (73.3%) experienced TI following medical advice, while the remaining patients stopped antiretroviral therapy (ART) of their own accord. The main justifications for TI were: ARV-related toxicities (38.7%), good laboratory parameters (30%) and poor adherence (20%). DNA sequencing of the partial pol gene was successful in 137 (91.3%) patients, of whom 38 (27.7%) presented mutations conferring ARV resistance. A higher viral load prior to TI correlated with drug resistance (P < 0.05). Our results demonstrate that there are diverse rationales for TI and that detection of resistant strains during TI most likely indicates a fitter virus than the wild type. High viral loads coupled with unprotected sex in this group could increase the likelihood of transmission of drug-resistant virus. Thus, treating physicians should be alerted to this problem when the use of ARVs is interrupted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / administration & dosage*
  • Brazil
  • CD4 Lymphocyte Count
  • Drug Administration Schedule
  • Drug Resistance, Viral
  • Female
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV-1 / genetics*
  • Humans
  • Male
  • Medication Adherence
  • Middle Aged
  • RNA, Viral / blood
  • RNA, Viral / genetics
  • Viral Load
  • pol Gene Products, Human Immunodeficiency Virus / genetics

Substances

  • Anti-Retroviral Agents
  • RNA, Viral
  • pol Gene Products, Human Immunodeficiency Virus